Love v. Wolf

249 Cal. App. 2d 822, 58 Cal. Rptr. 42, 1967 Cal. App. LEXIS 2294
CourtCalifornia Court of Appeal
DecidedMarch 30, 1967
DocketCiv. 11288
StatusPublished
Cited by33 cases

This text of 249 Cal. App. 2d 822 (Love v. Wolf) is published on Counsel Stack Legal Research, covering California Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Love v. Wolf, 249 Cal. App. 2d 822, 58 Cal. Rptr. 42, 1967 Cal. App. LEXIS 2294 (Cal. Ct. App. 1967).

Opinion

BRAY, J.

Defendant Wolf appeals from an order granting plaintiff a new trial and defendant Parke-Davis and Company appeals from the judgment in favor of plaintiff in the sum of $180,000 and from the order granting plaintiff a new trial on the issue of damages 1

Questions Presented

A. Wolf appeal from order granting new trial.

1. Alleged abuse of discretion in granting new trial.

B. Defendant Parke-Davis appeal from judgment.

1. Alleged errors in admission of evidence.

(a) Later warning label.

(b) Dr. Wolf’s testimony concerning the warnings.

2. Befusal to give a certain instruction.

3. Alleged misconduct of judge.

4. Were the verdicts inconsistent ?

C. Defendant Parke-Davis appeal from order granting new trial on damages alone.

1. Effect of section 573 of the Probate Code.

2. Plaintiff’s waiver of right to limited new trial.

D. The partial satisfaction of judgment.

Record

Plaintiff Carney L. Love (Mrs. Love) filed this action against defendant John Wolf, a medical doctor, and defendant Parke-Davis and Company (Parke-Davis), a pharmaceutical company, for damages alleged to have been sustained by plaintiff when she developed aplastic anemia following the *827 administration of an antibiotic, Chloromycetin, prescribed by Dr. Wolf and manufactured by Parke-Davis. At a first trial plaintiff recovered judgment against both defendants for $334,046. This judgment was reversed on appeal because of misconduct of plaintiff’s trial attorney. (Love v. Wolf (1964) 226 Cal.App.2d 378 [38 Cal.Rptr. 183].) At the second trial, the subject of this appeal, plaintiff recovered a judgment of $180,000 against Parke-Davis. Dr. Wolf obtained a defense verdict. On plaintiff’s motion the trial court ordered a new trial as to Dr. Wolf and a new trial as to Parke-Davis on the issue of damages only. Bach defendant separately appealed.

Chloromycetin is the trade name for Chloramphenicol. It is a “broad spectrum” antibiotic drug, meaning that it is an agent effective to kill or stop the growth of a wide variety of disease-causing organisms in human beings. This drug was developed and is exclusively manufactured by Parke-Davis. It may be administered only by doctors or on their prescriptions.

In 1952, three years after the introduction of the drug, instances had been reported of association of aplastic anemia with its use. Aplastic anemia is one of a number of “blood dyscrasias” (ill condition of the blood). The Pood and Drug Administration caused an investigation to be made of the drug and its association with aplastic anemia. Thereafter the Pood and Drug Administration decided that it had “weighed the value of the drug against its capabilities for causing harm and has decided that it should continue to be available for careful use by the medical profession in those serious and sometimes fatal diseases in which its use is necessary. ’ ’

The drug is required to be manufactured in accordance with standards prescribed by the administration and before the drug can be distributed it must be tested by it and certified as having such characteristics of strength, quality and purity to insure safety and efficacy of use as are prescribed in the regulation. A specified cautionary warning for circulars or packages and labels is prescribed by the administration. The required language of these is set forth in Love v. Wolf, supra, page 383. Parke-Davis complied with this directive. It is conceded that the drug used in this case was pure and uncontaminated.

Aplastic anemia is very rare, about 1,000 fatal cases from that cause being noted in this country yearly. In 1952 ParkeDavis sent letters to 200,000 physicians advising them ‘ ‘ of the association between Chloromycetin and aplastic anemia (also *828 other blood dyserasias) stating the number of cases was unknown ‘but it recognized that many have terminated fatally.’ It particularly warned of dangers from ‘intermittent therapy for minor infections.’ It pointed to indications of a ‘ calculated risk involved in the use of this potent antibiotic so that alert clinical observations and adequate blood studies should be made to detect any depression of bone marrow function as early as possible, and before any irreversible state occurs.’ This was followed by another similar letter on August 12, 1952. The first letter promised: ‘as information accumulates from continuing studies on the relation of blood disorders to Chloromycetin it will be disseminated promptly through appropriate channels. ’

‘ ‘ These letters were intended to reach all doctors and pharmacists in the United States. They were supplemented by full-page announcements in the American Medical Association Journal. Advertisements and promotional material distributed by the company since 1952 have contained a condensed warning similar to that on the packages and the labels.” (226 Cal.App.2d, pp. 383-384.)

In August 1958 plaintiff had several teeth extracted. An infection or inflammation developed in one of the sockets. She consulted Dr. Wolf who had previously treated her for another ailment. He prescribed Chloromycetin. The prescription was refilled. On November 4, 1958, plaintiff consulted Dr. Wolf for bronchitis. He again prescribed Chloromycetin. The prescription was refilled several times. Altogether 96 capsules of 250 milligrams each were dispensed to plaintiff. The pharmacist who sold the drug to plaintiff was joined in this action as a defendant. At the first trial the jury’s verdict was in his favor and was not appealed. Dr. Wolf last saw plaintiff professionally in December 1958. In the spring of 1959 aplastic anemia was diagnosed. She had been under treatment for aplastic anemia until the time of her death, subsequent to the rendition of judgment herein.

In its appeal from the judgment of liability Parke-Davis does not claim insufficiency of the evidence to support the judgment. It therefore becomes unnecessary to discuss the evidence in detail. While the evidence at the second trial was not precisely the same as at the first trial, it was sufficiently similar that the recital of the first trial evidence in Love v. Wolf, supra, 226 Cal.App.2d 378, gives an excellent idea of the evidence adduced at the second trial justifying a finding by the jury of overprescription by Dr. Wolf proximately caused by overpromotion of the drug by Parke-Davis.

*829 A. Dr. Wolf Appeal.

1. No abuse of discretion in granting new trial.

In his opening brief defendant Wolf (citing Arroyo v. Arden Farms Co.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Shin v. State Farm General Ins. Co. CA4/1
California Court of Appeal, 2023
Rupasinghe v. City of Los Angeles CA2/5
California Court of Appeal, 2021
Pacific Corporate Group Holdings v. Keck
232 Cal. App. 4th 294 (California Court of Appeal, 2014)
Frank E. Rogozienski, Inc. v. Hylton CA4/1
California Court of Appeal, 2014
Bland v. Davison County
1997 SD 92 (South Dakota Supreme Court, 1997)
Sullivan v. Delta Air Lines, Inc.
935 P.2d 781 (California Supreme Court, 1997)
Kellogg v. Asbestos Corp. Ltd.
41 Cal. App. 4th 1397 (California Court of Appeal, 1996)
Engle v. Endlich
9 Cal. App. 4th 1152 (California Court of Appeal, 1992)
Beavers v. Allstate Insurance
225 Cal. App. 3d 310 (California Court of Appeal, 1990)
Finn v. G. D. Searle & Co.
677 P.2d 1147 (California Supreme Court, 1984)
Fiorentino v. A. E. Staley Manufacturing Co.
416 N.E.2d 998 (Massachusetts Appeals Court, 1981)
Knox v. County of Los Angeles
109 Cal. App. 3d 825 (California Court of Appeal, 1980)
Valdez v. J. D. Diffenbaugh Co.
51 Cal. App. 3d 494 (California Court of Appeal, 1975)
Sven Sterner v. U.S. Plywood-Champion Paper, Inc.
519 F.2d 1352 (Eighth Circuit, 1975)
Self v. General Motors Corp.
42 Cal. App. 3d 1 (California Court of Appeal, 1974)
Stevens v. Parke, Davis & Co.
507 P.2d 653 (California Supreme Court, 1973)
Robinson v. Williamsen Idaho Equipment Company
498 P.2d 1292 (Idaho Supreme Court, 1972)
Incollingo v. EWING
282 A.2d 206 (Supreme Court of Pennsylvania, 1971)

Cite This Page — Counsel Stack

Bluebook (online)
249 Cal. App. 2d 822, 58 Cal. Rptr. 42, 1967 Cal. App. LEXIS 2294, Counsel Stack Legal Research, https://law.counselstack.com/opinion/love-v-wolf-calctapp-1967.